PolymarketKullanılabilirliği kontrol etKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreGüncel ima edilen olasılık
December 31, 67%3 seçenek arasında lider
December 31, 67%Piyasa kalitesi
63 / 100
Orta kalite24s Hacim
₺15,2 B
Likidite
₺1,1 Mn
Orta likiditeSpread
1.0 pt
Dar spreadYorumlar
0
Piyasa verileri
15 dakika önce güncellendi
19 Ağu 26 17:49 UTC1 Oca 28 04:59 UTC
Trendler
İşlem platformu koşulları
Kaynak: Polymarket
Bu koşullar yalnızca bilgi amaçlıdır; CoinRithm deneme işlemlerinde kendi kurallarını uygular.
- Minimum emir (pay):
- 5
- Fiyat adımı:
- 1 yüzde puan
- İşlem ücreti:
- Evet
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsKurallar
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
